Leflunomide in Takayasu arteritis - A long term observational study;Leflunomida na arterite de Takayasu - Estudo observacional de longo prazo

Revista Brasileira de Reumatologia

Volumn 56, Issue 4, 2016, Pages 371-375

  de Souza, Alexandre Wagner Silva ^a   de Almeida Agustinelli, Renan ^a   de Cinque Almeida, Hemerli ^a   Oliveira, Patrícia Bermudes ^a   Pinheiro, Frederico Augusto Gurgel ^a   Oliveira, Ana Cecilia Diniz ^a   Sato, Emilia Inoue ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Leflunomide; Systemic vasculitis; Takayasu arteritis; Therapy

Indexed keywords

LEFLUNOMIDE; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; PREDNISONE;

AGE; AORTA ARCH SYNDROME; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; OBSERVATIONAL STUDY; OPEN STUDY; RELAPSE; REMISSION; UNSPECIFIED SIDE EFFECT; AORTIC ARCH SYNDROME; TREATMENT OUTCOME;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LONGITUDINAL STUDIES; PREDNISONE; TAKAYASU ARTERITIS; TREATMENT OUTCOME;

EID: 85011289590     PISSN: 04825004     EISSN: 18094570     Source Type: Journal    
DOI: 10.1016/j.rbr.2015.09.007     Document Type: Article

References (15)

1. Kerr G.S., Hallahan C.W., Giordano J., Leavitt R.Y., Fauci A.S., Rottem M., et al. Takayasu's arteritis. Ann Intern Med. 1994, 120:919-929.
2. de Souza A.W., de Carvalho J.F. Diagnostic and classification criteria of Takayasu's arteritis. J Autoimmun. 2014, 48-49:79-83.
3. Direskeneli H., Aydin S.Z., Merkel P.A. Assessment of disease activity and progression in Takayasu's arteritis. Clin Exp Rheumatol. 2011, 29(1 Suppl 64):S86-S91.
4. Maksimowicz-McKinnon K., Hoffman G.S. Takayasu's arteritis: what is the long-term prognosis?. Rheum Dis Clin North Am. 2007, 33:777-786.
5. Maksimowicz-McKinnon K., Clark T.M., Hoffman G.S. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu's arteritis patients. Arthritis Rheum. 2007, 56:1000-1009.
6. Keser G., Direskeneli H., Aksu K. Management of Takayasu's arteritis: a systematic review. Rheumatology (Oxford). 2014, 53:793-801.
7. de Souza A.W., da Silva M.D., Machado L.S., Oliveira A.C., Pinheiro F.A., Sato E.I. Short-term effect of leflunomide in patients with Takayasu's arteritis: an observational study. Scand J Rheumatol. 2012, 41:227-230.
8. Arend W.P., Michel B.A., Bloch D.A., Hunder G.G., Calabrese L.H., Edworthy S.M., et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu's arteritis. Arthritis Rheum. 1990, 33:1129-1134.
9. Misra R., Danda D., Rajappa S.M., Ghosh A., Gupta R., Mahendranath K.M., et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford). 2013, 52:1795-1801. Indian Rheumatology Vasculitis (IRAVAS) group.
10. Direskeneli H., Aydin S.Z., Kermani T.A., Matteson E.L., Boers M., Herlyn K., et al. Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol. 2011, 38:1471-1479.
11. Hoffman G.S., Leavitt R.Y., Kerr G.S., Rottem M., Sneller M.C., Fauci A.S. Treatment of glucocorticoid-resistant or relapsing Takayasu's arteritis with methotrexate. Arthritis Rheum. 1994, 37:578-582.
12. Valsakumar A.K., Valappil U.C., Jorapur V., Garg N., Nityanand S., Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol. 2003, 30:1793-1798.
13. Shinjo S.K., Pereira R.M., Tizziani V.A., Radu A.S., Levy-Neto M. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu's arteritis. Clin Rheumatol. 2007, 26:1871-1875.
14. Goel R., Danda D., Mathew J., Edwin N. Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol. 2010, 29:329-332.
15. Clifford A., Hoffman G.S. Recent advances in the medical management of Takayasu's arteritis: an update on use of biologic therapies. Curr Opin Rheumatol. 2014, 26:7-15.